Iām banking on 30 million ounces
Iāve been thinking Havieron is a monster not just large!
If youāve researched this share like I have for the last few years you will understand that we are sitting on silly amounts of gold and copper and the fun bit is itās getting bigger every day!!
Share price irrelevant for me Iām afraid until it cruises past 70/80p in a few years
I think this means we are about to find out exactly how good avactas products are doing in the next few days!!!
Itās simpleā¦..if they are as good as everyone thinks then we will surely get fast tracked.
Interesting
If you press the buttonāpresentationā you will get this
583 / 17 - AVA3996, a novel pre|CISIONā¢ medicine, targeted to the tumor microenvironment via fibroblast activation protein (FAP) mediated cleavage
David H. Jones, Marine HouƩe, Hanna Buist, Sergi Marco, Chiara Braconi, Neil Bell, Francis X. Wilson, Fiona McLaughlin. Avacta Life Sciences, London, United Kingdom, University of Glasgow, Wolfson Wohl Cancer Research Centre, Glasgow, Scotland, United Kingdom
From aacr
AVA3996 has the potential to deliver elevated, effective levels of proteasome inhibitor directly to the solid tumor microenvironment while reducing systemic exposure and hence associated toxicities.
We have demonstrated that the pre|CISIONā¢ substrate is exquisitely sensitive to FAP and is not cleaved by related proteases. The active AVA3996 warhead should therefore be released primarily following FAP cleavage in the tumor microenvironment.
Cancer cell lines were assessed for their sensitivity to AVA3996 in vitro: activity was typically 100-fold less than the active warhead or Bortezomib alone. Upon co-incubation with soluble FAP, potency of AVA3996 increased to similar levels as seen for the warhead alone demonstrating the masking effect of the pre|CISIONā¢ substrate. A DRF/MTD study established the maximum tolerated dose in rats was around 6-fold higher for AVA3996 compared to warhead alone. This provides further evidence that AVA3996 can be dosed at higher levels than proteasome inhibitor alone, with the potential for greater tumor targeting and hence reduced systemic toxicity.
Ongoing in vivo and co-culture studies aim to further validate the efficacy and tolerability profile of AVA3996 to direct future development of this drug. In addition, the data supports wider utility of the pre|CISIONā¢ platform to target therapeutics to the tumor while reducing systemic dose-limiting toxicities.
Exactly bamps
The share price is irrelevant now unless you need the money to get out
Look on the bright side its 7p and that is utterly ridiculous or utterly amazing
Iām just buying at these prices whenever I can until they go bankrupt!!!
Long term holder here!!
Iām also not sure if people know how shorting/spread betting works
Itās a big part of lse bulletin boards and others
Some are very clever and some are extremely dumb
Either way if youāve done your research on a company they mean zilch